A HR20031 FE Study on Healthy Subjects

Shandong Suncadia Medicine

Status and phase: Completed; Phase 1

Conditions: Type 2 Diabetes

Treatments: Drug: HR20031 FDC

Study type: Interventional

Funder types: Industry

Identifiers

NCT05692934

HR20031-102

Details and patient eligibility

About

The purpose of this study is to assess the effect of food on the single-dose PK of SHR3824, SP2086 and metformin in the HR20031 FDC tablets in healthy subjects.

Enrollment: 40 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Sign the informed consent before the trial, and fully understand the content, process and possible adverse reactions of the trial. Must be able to communicate with the investigator, understand and comply with all study requirements;
2. Male or female subjects aged 18 to 45 (including 18 and 45);
3. Weigh at least 50 kg (for male) and 45 kg (for female), respectively, and have a body mass index (BMI) ≥ 19 and ≤26 kg/m2. BMI = weight (kg)/[height (m)]2;
4. Fasting plasma glucose in the range of 3.9-6.1 mmol/L.
5. According to medical history, physical examination, laboratory tests, 12-lead electrocardiogram, chest X-ray, and vital signs, the investigators determined that the subjects met the health criteria.

Exclusion criteria

1. Subject (include their fere) have pregnancy plan from 2 weeks prior to dose administration to follow-up period and refuse to use effective form of birth control;
2. Those who have a positive urine drug screen or have a history of drug abuse;
3. Excessive smoking (≥ 5 cigarettes/day);
4. History of alcoholism or regular alcohol consumption within 1 month before screening, that is, drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer with 5% alcohol or 45 mL of spirits with 40% alcohol or 150 mL of wine with 12% alcohol)
5. Subjects who took any beverage or food containing grapefruit, xanthine, caffeine, or alcohol within 48 hours before dosing or other factors which affect drug absorption, distribution, metabolism, excretion, etc
6. Subjects with medical conditions that may affect the absorption, distribution, metabolism, and excretion of the drug or impair adherence to the drug as judged by the investigator or deemed inappropriate by the investigator;
7. Subjects with poor compliance or other reasons deemed by the investigator to be unfit for the trial;
8. Viral hepatitis (including hepatitis B and C), AIDS antibody, and Treponema pallidum antibody screening are positive;
9. Clinical laboratory tests have clinically significant abnormalities;
10. Abnormal ECG has clinical significance;
11. Other clinical findings before screening show clinical significance for the following diseases (including but not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, Mental or cardiovascular disease);
12. History of allergy to test drugs, allergic constitution (multiple drug and food allergies);
13. Subjects who undergone any surgery within 3 months before screening, have not recovered from surgery, or have plans to surgery or hospitalization during the trial;
14. Donate blood or lose a lot of blood (>400mL) within three months before screening;
15. Subjects with a history of severe hypoglycaemia;
16. Subjects with a history of recurrent urinary tract infection or/and genital fungal infection;
17. Participated in the drug clinical trial and have taken drug or within three months before taking the research drug;
18. Take any prescription drugs, any vitamin products or herbal medicines within 14 days before screening or take any over-the-counter drugs within 1 month before screening;
19. Exposure to metformin and/or SGLT2 inhibitors such as dapagliflozin, empagliflozin, canagliflozin, ertugliflozin, and DPP-IV inhibitors such as sitagliptin, saxagliptin, linagliptin, or vildagliptin within 1 month before screening.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

40 participants in 4 patient groups

HR20031 FDC 10/100/1000 mg in the fast state

Experimental group

Treatment:

Drug: HR20031 FDC

Drug: HR20031 FDC

Drug: HR20031 FDC

Drug: HR20031 FDC

HR20031 FDC 10/100/1000 mg in the fed state

Experimental group

Treatment:

Drug: HR20031 FDC

Drug: HR20031 FDC

Drug: HR20031 FDC

Drug: HR20031 FDC

HR20031 FDC 5/50/750 mg*2 in the fast state

Experimental group

Treatment:

Drug: HR20031 FDC

Drug: HR20031 FDC

Drug: HR20031 FDC

Drug: HR20031 FDC

HR20031 FDC 5/50/750 mg*2 in the fed state

Experimental group

Treatment:

Drug: HR20031 FDC

Drug: HR20031 FDC

Drug: HR20031 FDC

Drug: HR20031 FDC